Chemical Abstracts Service introduced SciPlanner, an interactive workspace that enables scientists to more quickly identify synthesis options for designing the best research pathways and approaches.
Thermo Fisher Scientific Inc. introduced its Smart-Vue wireless monitoring solution. Smart-Vue protects precious samples by monitoring key laboratory parameters including temperature, CO2 concentration, humidity and differential pressure.
Gilead Sciences, Inc. and MicroDose Therapeutx, Inc. announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637.
Cumberland Pharmaceuticals Inc. said it acquired the rights to a molecule named ifetroban and will test it as a potential in-hospital treatment for a condition that involves progressive kidney failure.
Two new studies highlight the power of sequencing cancer patients' genomes as a diagnostic tool, helping doctors decide the best course of treatment and researchers identify new cancer susceptibility mutations that can be passed from parent to child.
NeuroVive Pharmaceutical and Hospices Civils de Lyon has dosed the first of 1,000 enrollees in its phase 3 trial of CicloMulsion for patients undergoing PCI for acute myocardial infarction to examine cyclosporine's ability to protect cardiac tissue.
Anavex Life Sciences Corp. announced that the first healthy human volunteers have been initially dosed in its Phase 1 clinical trial to evaluate ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease.
Forest Laboratories Inc. said its net income jumped in the fiscal fourth quarter compared to last year, when it made a large payment to AstraZeneca PLC to get the rights to a potential antibacterial drug cocktail.
Drug and medical device maker Abbott Laboratories said its first-quarter net income fell 14 percent on restructuring and acquisition costs and other expenses. For the period ended March 31, the company earned $864 million, or 55 cents per share.
A massive database cataloging the human genome's functional elements—including genes, RNA transcripts, and other products—is being made available as an open resource to the scientific community, classrooms, science writers, and the public.
A study of European HIV-positive children shows that 12% of children (around 1 in 8) develop triple-class virological failure by 5 years after starting their antiretroviral drug treatment program.
An Ohio State biophysicist used a supercomputer to search thousands of molecular combinations for the best configuration to block a protein that can cause breast or prostate cancer.
Researchers have found a new way to force cancer cells to self-destruct. Low doses of an anti-cancer drug currently in development sensitizes tumor cells to a second drug, called TRAIL, also being developed as a cancer treatment.
Stanford researchers have developed a new biosensor microchip that could significantly speed up the process of drug development. The microchips, packed with highly sensitive "nanosensors," analyze how proteins bind to one another.